HALOZYME REPORTS FOURTH QUARTER AND FULL-YEAR 2018 RESULTS
- ENHANZE® Technology Licensed to argenx for up to Three Targets, Including Named target FcRn, Resulting in Upfront Payment of $30 Million -
- 2019 Guidance Raised for Net Revenue and Year End Cash Balance to Reflect Latest Collaboration -
- Enrollment Completed in HALO-301 with Data Projected in Second Half of 2019 -
- Finished 2018 in Strong Financial Position with $355 Million in Cash, Cash Equivalents and Marketable Securities -
SAN DIEGO, February 21, 2019 - Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results for the fourth quarter and full year ended December 31, 2018 and provided an update on recent corporate activities.
"Our latest collaboration with argenx demonstrates the broad applicability of our ENHANZE® drug delivery technology and is a great way to start the year,” said Dr. Helen Torley, president and chief executive officer. ”We anticipate multiple additional key milestones in our ENHANZE® business including potential approval of Herceptin® SC later this quarter and potential regulatory submissions for a subcutaneous formulation of Darzalex® in the second half of the year. With a total of nine ENHANZE® collaborations spanning from established products to new, innovative therapies addressing unmet needs, we remain confident in the potential for $1 billion in royalty revenue in 2027.”
“Our PEGPH20 oncology program achieved a critical milestone during the fourth quarter with the completion of enrollment in our pivotal HALO-301 pancreas cancer study with approximately 500 patients. We also reached agreement with the FDA to change the primary endpoint for HALO-301 to a single primary endpoint of overall survival (OS), which we believe incrementally de-risked the study. We look forward with excitement to topline results from HALO-301, which we currently project in the second half of 2019.”
The following information was filed by Halozyme Therapeutics Inc (HALO) on Thursday, February 21, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Halozyme Therapeutics Inc's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed, and by Halozyme Therapeutics Inc.
Form Type: 10-K Annual Report Accession Number: 0001159036-19-000006 Submitted to the SEC: Thu Feb 21 2019 11:16:40 AM EST Accepted by the SEC: Thu Feb 21 2019 Period: Monday, December 31, 2018 Industry: Biological Products No Disgnostic Substances